212 related articles for article (PubMed ID: 10091800)
21. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
Hibi H; Okamura K; Takashi M; Shimoji T; Miyake K
Hinyokika Kiyo; 1997 Feb; 43(2):89-96. PubMed ID: 9086342
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin-based chemotherapy for the treatment of advanced transitional-cell carcinoma of the urinary tract--a preliminary report.
Lee MH; Chen MT; Chen KK; Lin AT; Lee YH; Lee LM; Chang YM; Chang LS; Liu JM; Hsieh RK
Cancer Chemother Pharmacol; 1992; 30 Suppl():S81-4. PubMed ID: 1394825
[TBL] [Abstract][Full Text] [Related]
23. [Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity].
Igawa M; Kadena H; Ohkuchi T; Ueda M; Usui T
Nihon Hinyokika Gakkai Zasshi; 1991 Oct; 82(10):1627-36. PubMed ID: 1770701
[TBL] [Abstract][Full Text] [Related]
24. [Clinical evaluation of M-VAC chemotherapy (methotrexate, vinblastine, adriamycin and cisplatin) for advanced urothelial cancer].
Gohji K; Takenaka A; Goto A; Hara I; Matsumoto O; Kamidono S; Hamami G; Itani A; Harada K; Tadera N
Nihon Hinyokika Gakkai Zasshi; 1989 Mar; 80(3):321-8. PubMed ID: 2659869
[TBL] [Abstract][Full Text] [Related]
25. [Results of modified M-VAC chemotherapy for advanced urothelial carcinoma].
Miura N; Numata K; Azuma K; Hashine K; Sumiyoshi Y
Nihon Hinyokika Gakkai Zasshi; 2007 May; 98(4):589-94. PubMed ID: 17564101
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
[TBL] [Abstract][Full Text] [Related]
27. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
[TBL] [Abstract][Full Text] [Related]
28. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
Scher HI
J Urol; 1992 Nov; 148(5):1625-6. PubMed ID: 1433578
[No Abstract] [Full Text] [Related]
29. Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in advanced, measurable breast carcinoma.
Langer CJ; Catalano R; Weiner LM; Scher R; Bagchi P; Saren B; Comis RL
Cancer Invest; 1995; 13(2):150-9. PubMed ID: 7874568
[TBL] [Abstract][Full Text] [Related]
30. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.
Siefker-Radtke AO; Millikan RE; Tu SM; Moore DF; Smith TL; Williams D; Logothetis CJ
J Clin Oncol; 2002 Mar; 20(5):1361-7. PubMed ID: 11870180
[TBL] [Abstract][Full Text] [Related]
31. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.
Sternberg CN; de Mulder P; Schornagel JH; Theodore C; Fossa SD; van Oosterom AT; Witjes JA; Spina M; van Groeningen CJ; Duclos B; Roberts JT; de Balincourt C; Collette L;
Eur J Cancer; 2006 Jan; 42(1):50-4. PubMed ID: 16330205
[TBL] [Abstract][Full Text] [Related]
32. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
Sella A; Flex D; Gafni D; Rabinovitz O; Sulkes A; Baniel J
Harefuah; 1999 Feb; 136(4):268-71, 340, 339. PubMed ID: 10914214
[TBL] [Abstract][Full Text] [Related]
33. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer.
Miyanaga N; Akaza H; Shimazui T; Ohtani M; Koiso K
Cancer Chemother Pharmacol; 1994; 35 Suppl():S5-8. PubMed ID: 7527735
[TBL] [Abstract][Full Text] [Related]
34. [Gemcitabine and cisplatin therapy in advanced or metastatic urothelial cancer: comparison of side effect with MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin)].
Ochi T; Ozawa A; Tanji N; Yanagihara Y; Yanagaki T; Miyauchi Y; Ikeda T; Shimamoto K; Toshino A; Sugawara T; Hamada H; Yokoyama M
Nihon Hinyokika Gakkai Zasshi; 2006 Sep; 97(6):777-81. PubMed ID: 17025209
[TBL] [Abstract][Full Text] [Related]
35. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
Hsu CH; Chen J; Wu CY; Cheng AL; Pu YS
Anticancer Res; 2001; 21(1B):711-5. PubMed ID: 11299831
[TBL] [Abstract][Full Text] [Related]
36. Primary transitional cell carcinoma of prostate: case with lymph node metastasis eradicated by neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) therapy.
Takashi M; Sakata T; Nagai T; Kato T; Sahashi M; Koshikawa T; Miyake K
Urology; 1990 Jul; 36(1):96-8. PubMed ID: 2368239
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors.
Scher HI; Yagoda A; Herr HW; Sternberg CN; Morse MJ; Sogani PC; Watson RC; Reuter V; Whitmore WF; Fair WR
J Urol; 1988 Mar; 139(3):475-7. PubMed ID: 3343729
[TBL] [Abstract][Full Text] [Related]
38. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience.
Boutan-Laroze A; Mahjoubi M; Droz JP; Charrot P; Fargeot P; Kerbrat P; Caty A; Voisin PM; Spielmann M; Rey A
Eur J Cancer; 1991; 27(12):1690-4. PubMed ID: 1782084
[TBL] [Abstract][Full Text] [Related]
39. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
Bellmunt J; Ribas A; Eres N; Albanell J; Almanza C; Bermejo B; Solé LA; Baselga J
Cancer; 1997 Nov; 80(10):1966-72. PubMed ID: 9366300
[TBL] [Abstract][Full Text] [Related]
40. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer.
Igawa M; Ohkuchi T; Ueki T; Ueda M; Okada K; Usui T
J Urol; 1990 Sep; 144(3):662-5. PubMed ID: 2388322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]